Abstract
INTRODUCTION
The Alzheimer’s Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer’s disease (AD) prevention. The studies were terminated early, and the reversibility of umibecestat’s side effects was assessed.
METHODS
Cognitively unimpaired 60- to 75-year-old apolipoprotein E (APOE) ε4 homozygotes and heterozygotes (the latter with elevated brain amyloid deposition) (n = 1556) received umibecestat (50 or 15 mg daily) or placebo for 7 months on average and were followed for a median (interquartile range) of 4 (3 to 6) months after washout.
RESULTS
Compared to placebo, umibecestat-treated participants had small, non-progressive, but statistically significant decline in performance on certain cognitive batteries including Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and API Preclinical Composite Cognitive test, but not Clinical Dementia Rating-Sum of Boxes. RBANS differences were no longer significant at the end of follow-up.
DISCUSSION
In people at genetic risk for AD, high-dose beta-site amyloid precursor protein cleaving enzyme (BACE) inhibition was associated with early mild cognitive worsening, which reversed shortly after washout, suggesting a symptomatic side effect not associated with neurodegeneration. Fully anonymized data, images, and samples are available upon request for further research on BACE inhibition.
Highlights
This is the first trial with blinded assessment of reversibility of BACE inhibitor side effects.
Umibecestat was tested in cognitively unimpaired persons at genetic risk for AD.
Umibecestat led to early mild cognitive decline that reversed shortly after washout.
This suggests a potentially manageable effect not associated with neurodegeneration.
Further research may determine the future of BACE inhibition in AD prevention.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Pierre N. Tariot,
Marie‐Emmanuelle Riviere,
Stephen Salloway,
Jeffrey M. Burns,
Jón G. Snaedal,
Beth Borowsky,
Cristina Lopez Lopez,
Fonda Liu,
Marie‐Laure Rouzade‐Dominguez,
Pilar Cazorla,
Marie‐Catherine Mousseau,
Michal Arkuszewski,
Javier Ricart,
Vissia Viglietta,
Yihan Sui,
Angelika Caputo,
Jessica B. Langbaum,
Eric M. Reiman,
Ana Graf | September 25, 2024